The two key examples discussed above include prostate adenocarcinoma and EGFR mutant non-small cell lung cancer, two diseases where standard of care involves highly effective therapies targeting androgen receptor or EGFR signaling, respectively. Here, EGFR is linked to non-small cell lung carcinoma.